VEGFR and type-V RTK activation and signaling

Cold Spring Harbor Perspectives in Biology

Volumn 5, Issue 10, 2013, Pages

  Shibuya, Masabumi ^a,b  

^a JOBU UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLT1 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; FEMALE; HUMAN; KIDNEY; METABOLISM; PHYLOGENY; PHYSIOLOGY; PREECLAMPSIA; PREGNANCY; PROTEIN TERTIARY STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; FEMALE; HUMANS; KIDNEY; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; PHYLOGENY; PRE-ECLAMPSIA; PREGNANCY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84885028426     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a009092     Document Type: Article

References (91)

1. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. 1998. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci 95: 548-553.
2. Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A, Baffi JZ, Yamada K, Kaneko H, Green MG, et al. 2009. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 15: 1023-1030.
3. Alitalo K, Carmeliet P. 2002. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1: 219-227.
4. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, et al. 2006. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443: 993-997.
5. Azuma J, Taniyama Y, Takeya Y, Iekushi K, Aoki M, Dosaka N, Matsumoto K, Nakamura T, Ogihara T, Morishita R. 2006. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther 13: 1206-1213.
6. Barleon B, Sozzani S, Zhou D, Weich HA, Martovani A, Marme D. 1996. Migration of human monocytes in response to vascular endothelilal growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336-3343.
7. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kleckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, et al. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
8. Chappell JC, Taylor SM, Ferrara N, Bautch VL. 2009. Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell 17: 377-386.
9. Cho CH, Kim KE, Byun J, Jang HS, Kim DK, Baluk P, Baffert F, Lee GM, Mochizuki N, Kim J, et al.2005.Long-termand sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ Res 97: 86-94.
10. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS. 1998. Avascular en-dothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reproduct 59: 1540-1548.
11. Clauss M, Weich H, Breier G, Knies U, Röckl W, Walten-berger J, Risau W. 1996. The vascular endothelial growth factor receptor Flt-1 madiates biological activities. J Biol Chem 271: 17629-17634.
12. Cohen MH, Gootenberg J, Keegan P, Pazdur R. 2007. FDA drug approval summary: Bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12: 713-718.
13. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. 1992. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991.
14. Duchek P, Somogyi K, Jekely G, Beccari S, Rorth P. 2001. Guidance of cell migration by the Drosophila PDGF/ VEGF receptor. Cell 107: 17-26.
15. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K. 1998. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282: 946-949.
16. Dvorak HF. 2002. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380.
17. Ferrara N. 2004. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25: 581-611.
18. Ferrara N, Davis-Smyth T. 1997. The biology of vascular endothelial growth factor. Endocrine Rev 18: 4-25.
19. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442.
20. Fong GH, Rossant J, Gertsentein M, Breitman ML. 1995. Role of the Flt-1 receptor tyrosine kinase inregulating the assembly of vascular endothelium. Nature 376: 66-70.
21. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
22. Heldin CH, Westermark B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316.
23. Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Halmes-maki E. 2001. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 7: 205-210.
24. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. 1998. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci 95: 9349-9354.
25. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M, MS Min-cho, et al. 2002. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung specific metastasis. Cancer Cell 2: 289-300.
26. Hiratsuka S, Nakao K, Nakamura K, Katsuki M, Maru Y, Shibuya M. 2005. Membrane-fixation of VRGFR1 li-gand-binding domain is important for vasculogenesis/ angiogenesis in mice. Mol Cell Biol 25: 346-354.
27. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. 2000. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 80: 443-454.
28. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
29. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. 2000. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 67: 295-301.
30. Ishimaru S, Ueda R, Hinohara Y, Ohtani M, Hanafusa H. 2004. PVR plays a critical role via JNK activation in thorax closure during Drosophila metamorphosis. EMBO J 23: 3984-3994.
31. Jain RK. 2005. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307: 58-62.
32. Jakobsson L, Bentley K, Gerhardt H. 2009. VEGFRs and Notch: A dynamic collaboration in vascular patterning. Biochem Soc Trans 37: 1233-1236.
33. Jin J, Sison K, Li C, Tian R, Wnuk M, Sung HK, Jeansson M, Zhang C, Tucholska M, Jones N, et al. 2012. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell 151: 384-399.
34. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K. 1997. Proteo-lytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16: 3898-3911.
35. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827.
36. Karkkainen MJ, Jussila L, Ferrell RE, Finegold DN, Altalo K. 2001. Molecular regulation of lymphangiogenesis and targets for tissue oedema. Trends Mol Med 7: 18-22.
37. Kendall RL, Thomas KA. 1993. Inhibition of vascular endo-thelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci 90: 10705- 10709.
38. Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M, Tchaikovski V, Waltenberger J, Shibuya M, Plate KH, et al. 2008. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 68: 7342-7351.
39. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N. 1996. Identification of vascular endothelial growth factor determinanats for binding KDR and FLT-1 receptors. J Biol Chem 271: 5638-5646
40. Kiba A, Sagara H, Hara T, Shibuya M. 2003a. VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem Biophys Res Commun 301: 371-377.
41. Kiba A, Yabana N, Shibuya M. 2003b. A set of loop-1 and -3 structures in the novel VEGF family member, VEGF-ENZ7, is essential for the activation of VEGFR-2 signaling. J Biol Chem 278: 13453-13461.
42. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
43. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. 2003. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88: 2348-2351.
44. Kondo K, Hiratsuka S, Subbalakshmi E, Matsushime H, Shibuya M. 1998. Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene 208: 297-305.
45. Kunstfeld R, Hirakawa S, Hong YK, Schacht V, Lange-Asschenfeldt B, Velasco P, Lin C, Fiebiger E, Wei X, Wu Y, et al. 2004. Induction of cutaneous delayed-type hy-persensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 104: 1048-1057.
46. Lawson ND, Mugford JW, Diamond BA, Weinstein BM. 2003. Phospholipase C γ-1 is required downstream of vascular endothelial growth factor during arterial development. Genes Dev 17: 1346-1351.
47. Le Couter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, Ferrara N. 2003. Angiogenesis-indepen-dent endothelial protection of liver: Role of VEGFR-1. Science 299: 890-893.
48. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al. 2004. Circulating angiogenic factors and the risk of pre- eclampsia. N Engl J Med 350: 672-683.
49. Lohela M, Bry M, Tammela T, Alitalo K. 2009. VEGFs and receptors involved in angiogenesis versus lymphangio-genesis. Curr Opin Cell Biol 21: 154-165.
50. Lyttle DJ, Fraser KM, Fleming SB, Mercer AA, Robinson AJ. 1994. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 68: 84-92.
51. Mökinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, et al. 2001. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/ D receptor VEGFR-3. EMBO J 20: 4762-4773.
52. Matsumoto T, Bohman S, Dixelius J, Berge T, Dimberg A, Magnusson P, Wang L, Wikner C, Qi JH, Wernstedt C, et al. 2005. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J 24: 2342-2353.
53. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR. 1991. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci 88: 9026-9030.
54. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, et al. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658.
55. McColl BK, Paavonen K, Karnezis T, Harris NC, Davydova N, Rothacker J, Nice EC, Harder KW, Roufail S, Hibbs ML, et al. 2007. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J 21: 1088-1098.
56. Murakami M, Iwai S, Hiratsuka S, Yamauchi M, Nakamura K, Iwakura Y, Shibuya M. 2006. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of mono-cyte/macrophages. Blood 108: 1849-1856.
57. Muramatsu M, Yamamoto S, Osawa T, Shibuya M. 2010. VEGFR-1 signaling promotes mobilization of macro-phage-lineage cells from bone marrow and stimulates solid tumor growth. Cancer Res 70: 8211-8221.
58. Niida S, Kondo T, Hiratsuka S, Hayashi S-I, Amizuka N, Noda T, Ikeda K, Shibuya M. 2005. Vascular endothelial growth factor receptor-1 signaling is essential for osteo-clast development and bone-marrow formation in CSF-1-deficient mice. Proc Natl Acad Sci 102: 14016-14021.
59. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. 1998. A novel type of vascular endothelial growth factor: VEGF-E (NZ-7 VEGF) preferentially utilizes KDR/Flk-1receptorandcarriesapotentmitoticactivitywithout heparin-binding domain. J Biol Chem 273:31273-31282.
60. Osawa T, Muramatsu M, Watanabe M, Shibuya M. 2009. Hypoxia and low nutrition double stress induces aggressiveness in a murine model of melanoma. Cancer Sci 100: 844-851.
61. Risau W. 1997. Mechanism of angiogenesis. Nature 386: 671-674.
62. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT. 2002. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 16: 2684-2698.
63. Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M. 2005. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 invasculogenesis in mice. Proc Natl Acad Sci 102: 1076-1081.
64. + vascular progenitor cells. J Cell Sci 122: 3303-3311.
65. Sawano A, Takahashi T, Yamaguchi S, Aonuma T, Shibuya M. 1996. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor (PlGF), which is related to vascular endothelial growth factor (VEGF). Cell Growth Diff 7: 213-221.
66. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M.2001.Vascularendothelial growthfactorrecep-tor-1 (Flt-1) is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97: 785-791
67. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X-F, Breitman ML, Schuh AC. 1995. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66.
68. Shibuya M. 1995. Role of VEGF-Flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 67: 281-316.
69. Shibuya M. 2002.Vascular endothelial growth factor receptor family genes: When did the three genes phylogenet-ically segregate? Biol Chem 383: 1573-1579.
70. Shibuya M.2011. Involvement of Flt-1 (VEGFR-1)in cancer and preeclampsia. Proc Jpn Acad Ser B Phys Biol Sci 87: 167-178.
71. Shibuya M, Claesson-Welsh L. 2006. Signal transduction by VEGF receptors in regulation of angiogenesis and lym-phangiogenesis. Exp Cell Res 312: 549-560.
72. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Mat-sushime H, Sato M. 1990. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5: 519-524.
73. Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shi-buya M. 1998. Mapping of the sites involved in ligand-association and dissociation at the extracellular domain of vascularendothelial growth factor receptor KDR. JBiol Chem 273: 31283-31288
74. Stefater JA III, Lewkowich I, Rao S, Mariggi G, Carpenter AC, Burr AR, Fan J, Ajima R, Molkentin JD, Williams BO, et al. 2011. Regulationof angiogenesis bya non-canonical Wnt-Flt1 pathway inmyeloid cells. Nature 474: 511-515.
75. Takahashi T, Shibuya M. 1997. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-g pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 14: 2079-2089.
76. Takahashi T, Ueno H, Shibuya M. 1999. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18: 2221-2230.
77. Takahashi T, Yamaguchi S, Chida K, Shibuya M. 2001. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-g and DNA synthesis in vascular endothelial cells. EMBO J 20: 2768-2778.
78. Tanaka K, Yamaguchi S, Sawano A, Shibuya M. 1997. Characterization of the extracellular domain in the vascular endothelial growth factor receptor-1 (Flt-1 tyrosine ki-nase). Jpn J Cancer Res 88: 867-876.
79. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy R, Shows TB. 1991. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6: 1677-1683.
80. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, et al. 2011. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124: 940-950.
81. Tsuchida R, Das B, Yeger H, Koren G, Shibuya M, Thorner PS, Baruchel S, Malkin D. 2008. Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 au-tocrine signaling. Oncogene 27: 3923-3934.
82. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, et al. 2001. Signalling via vascular endothelial growth factor receptor-3 issufficient for lymphangiogen-esis in transgenic mice. EMBO J 20: 1223-1231.
83. Wang S, Li X, Parra M, Verdin E, Basel-Duby R, Olson EN. 2008. Control of endothelial cell proliferation and migra-tionby VEGF signalingto histone deacetylase7. Proc Natl Acad Sci 105: 7738-7743.
84. Wang F, Yamauchi M, Muramatsu M, Osawa T, Tsuchida R, Shibuya M. 2011. RACK1 regulates VEGF/Flt1-mediated cell migrationvia activationof a PI3K/Akt pathway.J Biol Chem 286: 9097-9106.
85. Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, Hick-lin DJ. 2006. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 119: 1519-1529.
86. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL. 1996. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98: 2018-2026.
87. Xiong Y, Huo Y, Chen C, Zeng H, Lu X, Wei C, Ruan C, Zhang X, Hu Z, Shibuya M, et al. 2009. VEGF receptor-2 Y1175 signaling controls VEGF-induced vWF release from endothelial cells via PLC-g1- and PKA-dependent pathways. J Biol Chem 284: 23217-23224.
88. Yamaguchi S, Iwata K, Shibuya M. 2002. Soluble Flt-1 (soluble VEGFR-1), a potent natural anti-angiogenic molecule in mammals, is phylogenetically conserved in avians. Bi-ochem Biophys Res Commun 291: 554-559.
89. Yang Y, Xie P, Opatowsky Y, Schlessinger J. 2010. Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling. Proc Natl Acad Sci 107: 1906-1911.
90. You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM. 2011. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 71: 4758-4768.
91. NZ7/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation. Arterioscler Thromb Vasc Biol 26: 2019-2026.